Anti-VEGF Receptor 3抗体(ab27278)
Key features and details
- Rabbit polyclonal to VEGF Receptor 3
- Suitable for: ICC/IF, WB, IHC-P, IHC - Wholemount
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
选择批间可重复性更高的重组抗体
- 研究可靠 —— 各批次间结果一致且可重复
- 长期批量供应 —— 采用重组技术，可实现快速生产
- 首次实验即可成功 —— 经过大量验证确认了特异性
- 符合伦理标准 —— 产品不含动物成分
概述
-
产品名称
Anti-VEGF Receptor 3抗体
参阅全部 VEGF Receptor 3 一抗 -
描述
兔多克隆抗体to VEGF Receptor 3 -
宿主
Rabbit -
经测试应用
适用于: ICC/IF, WB, IHC-P, IHC - Wholemountmore details -
种属反应性
与反应: Mouse, Rat, Human -
免疫原
Synthetic peptide within Human VEGF Receptor 3 aa 1250-1350. The exact sequence is proprietary.
Database link: P35916 -
阳性对照
- IHC-P: Human placenta tissue. ICC/IF: HeLa cells. WB: Hey cell lysate.
-
常规说明
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
存储溶液
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading... -
纯度
Immunogen affinity purified -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Compatible Secondaries
-
Isotype control
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab27278于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。
| 应用 | Ab评论 | 说明 |
|---|---|---|
| ICC/IF |
Use a concentration of 1 µg/ml.
|
|
| WB | (1) |
Use at an assay dependent concentration. Predicted molecular weight: 146 kDa.
|
| IHC-P | (5) |
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
| IHC - Wholemount | (1) |
Use at an assay dependent concentration.
|
| 说明 |
|---|
|
ICC/IF
Use a concentration of 1 µg/ml. |
|
WB
Use at an assay dependent concentration. Predicted molecular weight: 146 kDa. |
|
IHC-P
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
|
IHC - Wholemount
Use at an assay dependent concentration. |
靶标
-
功能
Receptor for VEGFC. Has a tyrosine-protein kinase activity. -
组织特异性
Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain. -
疾病相关
Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue. -
序列相似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
细胞定位
Membrane. - Information by UniProt
-
数据库链接
- Entrez Gene: 2324 Human
- Entrez Gene: 14257 Mouse
- Entrez Gene: 114110 Rat
- Omim: 136352 Human
- SwissProt: P35916 Human
- SwissProt: P35917 Mouse
- SwissProt: Q91ZT1 Rat
- Unigene: 646917 Human
see all -
别名
- EC 2.7.10.1 antibody
- flt 4 antibody
- FLT-4 antibody
see all
图片
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 3 antibody (ab27278)This image is courtesy of an anonymous AbreviewImmunohistochemistry analysis (Formalin/PFA-fixed paraffin-embedded sections) of paraformaldehyde fixed, 1% TritonX-100 in PBS permeabilized human glioblastoma tissue. Stained with ab27278 at 1/100 dilution. Secondary antibody used was Donkey Jackson Immuno Anti-rabbit at 1/500 dilution. Blocking was done with 3% donkey serum for 30 minutes at 25°C. The sample was incubated with the primary antibody and 1% donkey serum for 1 hour at 25°C. Antigen retrieval method was heat mediated Tris-EDTA
-
Western blot - Anti-VEGF Receptor 3 antibody (ab27278)All lanes : Anti-VEGF Receptor 3 antibody (ab27278) at 1/1000 dilution
Lane 1 : HEL 92.1.7 cell lysate
Lane 2 : MCF7 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 146 kDa
Observed band size: 200 kDa why is the actual band size different from the predicted?Anti-FLT4 antibody (ab27278) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab27278 was shown to bind specifically to FLT4 but with several non-specific bands. We recommend ab243232 for Western blot. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 3 antibody (ab27278)Ab27278 at a dilution of 1/100, staining formalin fixed paraffin embedded Flt4 in human placenta by Immunohistochemistry. -
Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 3 antibody (ab27278)ICC/IF image of ab27278 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab27278, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. -
Western blot - Anti-VEGF Receptor 3 antibody (ab27278)Anti-VEGF Receptor 3 antibody (ab27278) at 1/50 dilution
Predicted band size: 146 kDa
Observed band size: 170,200 kDa why is the actual band size different from the predicted?
Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1:50 for 2 hours at room tepterature Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1:50 for 2 hours at room temperature. The protein is heavily glycosylated and this might explain the increase in MW above the predcted MW as well as the multiple bands.
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (48)
ab27278 被引用在 48 文献中.
- Torres-Ruiz S et al. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. Int J Mol Sci 24:N/A (2023). PubMed: 36835014
- Huang B et al. ANRIL promotes the regulation of colorectal cancer on lymphatic endothelial cells via VEGF-C and is the key target for Pien Tze Huang to inhibit cancer metastasis. Cancer Gene Ther 30:1260-1273 (2023). PubMed: 37286729
- Vera Quesada CL et al. Widespread distribution of lymphatic vessels in human dura mater remote from sinus veins. Front Cell Dev Biol 11:1228344 (2023). PubMed: 37795263
- Mortensen ACL et al. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer. Sci Rep 13:16844 (2023). PubMed: 37803074
- Kim BH et al. Restoration of Homeostasis in the Tracheal Mucosa After Thyroid Surgery in a Rat Model. In Vivo 36:161-169 (2022). PubMed: 34972711